TrialCancer immunology, immunotherapy : CII2015

Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma.

Oliver Klein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.